FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
You may also be interested in...
Drug/Diagnostic Co-Development Guidance Coming Soon, But Could Be Outdated Quickly
Tests that look for many markers at one time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.
Drug/Diagnostic Co-Development Guidance Coming Soon, But Could Be Outdated Quickly
Tests that look for many markers at one time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.
FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development
A CDRH representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.